Market closedNon-fractional

Kymera Therapeutic/KYMR

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Kymera Therapeutic

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Ticker

KYMR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Watertown, United States

Employees

186

KYMR Metrics

BasicAdvanced
$1.9B
Market cap
-
P/E ratio
-$2.51
EPS
2.27
Beta
-
Dividend rate
$1.9B
2.27
9.571
9.309
10.845
12.236
-896.94%
-14.60%
-26.35%
23.41
2.62
2.62
-13.64
70.16%
-12.20%
17.22%
13.84%

What the Analysts think about KYMR

Analyst Ratings

Majority rating from 17 analysts.
Buy

KYMR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-475.49% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$10M
-78.66%
Net income
-$49M
239.16%
Profit margin
-475.49%
1,489.74%

KYMR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.08%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.67
-$0.90
-$0.25
-$0.69
-
Expected
-$0.64
-$0.64
-$0.41
-$0.73
-$0.68
Surprise
5.24%
40.33%
-38.27%
-5.08%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Kymera Therapeutic stock?

Kymera Therapeutic (KYMR) has a market cap of $1.9B as of July 05, 2024.

What is the P/E ratio for Kymera Therapeutic stock?

The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of July 05, 2024.

Does Kymera Therapeutic stock pay dividends?

No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Kymera Therapeutic dividend payment date?

Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.

What is the beta indicator for Kymera Therapeutic?

Kymera Therapeutic (KYMR) has a beta rating of 2.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Kymera Therapeutic stock

Buy or sell Kymera Therapeutic stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing